Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

AKO 003

Next Previous
Drug Profile

AKO 003

Alternative Names: AKO-003; ketamine based psychedelic formulation

Latest Information Update: 28 Sep 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Akome Biotech
  • Developer Akome Biotech; Complutense University Madrid; Core One Labs
  • Class Amines; Antidepressants; Behavioural disorder therapies; Chlorobenzenes; Cyclohexanes; Ketones; Neuroprotectants; Nootropics; Phytotherapies; Small molecules
  • Mechanism of Action AMPA receptor agonists; Antioxidants; Dopamine receptor agonists; NMDA receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Major depressive disorder

Most Recent Events

  • 28 Sep 2025 No recent reports of development identified for preclinical development in Major depressive disorder in Canada (Sublingual)
  • 04 Mar 2022 Akome Biotech and Universidad Complutense de Madrid agree to co-develop psychedelic compounds for the treatment of Alzheimer's disease, Parkinson's disease, major depressive disorder and ischaemic stroke
  • 04 Mar 2022 Preclinical trials in Major depressive disorder in Spain (Sublingual)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top